Contributions
Abstract: EP1313
Type: ePoster
Abstract Category: Clinical aspects of MS - 3 Paediatric MS
Background: Obesity is a recognised risk factor for the development of paediatric multiple sclerosis (MS). Obesity is associated with an increase in pro-inflammatory adipokines and also contributes to vitamin D deficiency. The aim of this study was to assess the trajectories of body mass index (BMI) in paediatric MS patients both prior to and post MS-onset.
Design and methods: A retrospective chart assessment was completed on 27 paediatric MS subjects and 100 healthy controls. Height and weight trajectories were collected on paediatric MS subjects prior to, at, and post-MS diagnosis. Paediatric MS subjects were excluded if disease duration was less than 2 years at the time of data collection. In addition, clinical demographics (age of first symptom, race/ethnicity, age of puberty, and Expanded Disability Status Scores (EDSS)) were collected. BMI categories were classified by the Center for Disease Control (CDC) growth charts with dependence upon subject age and sex.
Results: Of the 27 paediatric MS subjects, 33% were of normal BMI, 41% were overweight, and 26% were obese at the time of the first symptom of MS. At 2 years post-diagnosis, 30% of subjects were of normal weight, 30% were overweight, and 40% were obese. Of subjects who transitioned BMI categories over 2 years: all obese subjects remained obese, 36% (n=4) of overweight subjects became obese, and 11% (n=1) of normal weight subjects became overweight. No subject transitioned to a lower BMI status within 2 years of disease onset.
Conclusions: Paediatric MS subjects have high rates of being overweight or obese at disease onset. Despite low EDSS scores (all scores < 2.0), subjects of normal BMI at diagnosis tend to stay within a normal BMI range, whereas a third of our overweight subjects transitioned to obesity within 2 years of disease onset. Data analysis is ongoing for paediatric MS data prior to MS diagnosis in addition to the healthy control cohort.
Disclosure:
J.N. Brenton: Nothing to disclose
E. Woolbright: Nothing to disclose
M.D. Goldman: Nothing to disclose
Abstract: EP1313
Type: ePoster
Abstract Category: Clinical aspects of MS - 3 Paediatric MS
Background: Obesity is a recognised risk factor for the development of paediatric multiple sclerosis (MS). Obesity is associated with an increase in pro-inflammatory adipokines and also contributes to vitamin D deficiency. The aim of this study was to assess the trajectories of body mass index (BMI) in paediatric MS patients both prior to and post MS-onset.
Design and methods: A retrospective chart assessment was completed on 27 paediatric MS subjects and 100 healthy controls. Height and weight trajectories were collected on paediatric MS subjects prior to, at, and post-MS diagnosis. Paediatric MS subjects were excluded if disease duration was less than 2 years at the time of data collection. In addition, clinical demographics (age of first symptom, race/ethnicity, age of puberty, and Expanded Disability Status Scores (EDSS)) were collected. BMI categories were classified by the Center for Disease Control (CDC) growth charts with dependence upon subject age and sex.
Results: Of the 27 paediatric MS subjects, 33% were of normal BMI, 41% were overweight, and 26% were obese at the time of the first symptom of MS. At 2 years post-diagnosis, 30% of subjects were of normal weight, 30% were overweight, and 40% were obese. Of subjects who transitioned BMI categories over 2 years: all obese subjects remained obese, 36% (n=4) of overweight subjects became obese, and 11% (n=1) of normal weight subjects became overweight. No subject transitioned to a lower BMI status within 2 years of disease onset.
Conclusions: Paediatric MS subjects have high rates of being overweight or obese at disease onset. Despite low EDSS scores (all scores < 2.0), subjects of normal BMI at diagnosis tend to stay within a normal BMI range, whereas a third of our overweight subjects transitioned to obesity within 2 years of disease onset. Data analysis is ongoing for paediatric MS data prior to MS diagnosis in addition to the healthy control cohort.
Disclosure:
J.N. Brenton: Nothing to disclose
E. Woolbright: Nothing to disclose
M.D. Goldman: Nothing to disclose